Please assess the completion status of the following clinical trial:

Trial Title: Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pathologic confirmation of non-small lung cancer (all histologies)~* Age ≥ 18 years at the time of treatment at a COTA center~* Documentation of metastatic (stage IV) disease~* Untreated metastatic disease prior to the genomic testing. No treatment for metastatic lung cancer is permitted prior to genomic profiling. Prior therapy for stage 0-III lung cancer is permitted.~* Second malignancy eligible if prior malignancy has been stable off therapy for ≥ 6 months.~Exclusion Criteria:~* Small cell lung cancer histology~* Non-metastatic or completely resected lung cancer~* Treatment for metastatic disease prior to genomic testing.~* Active second malignancy requiring therapy less than 6 months prior to lung cancer diagnosis~* Patients may refuse to be tracked in the COTA database and/or participate in this observational study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A - Genomic profile by FoundationOne (Type: None): The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and an actionable target has been identified and the patient/physician agree to receive the targeted therapy
- B - Genomic profiling by FoundationOne (Type: None): The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and an actionable target has been identified. However, the patient does not receive the targeted therapy.
- C - Genomic profiling by FoundationOne (Type: None): The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and no actionable target has been identified.
- D - Genomic profile by other methods (Type: None): The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target has been identified and the patient/physician agrees to receive the targeted therapy.
- E - Genomic profile by other methods (Type: None): The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target has been identified. However, the patient does not receive targeted therapy.
- F - Genomic profile by other methods (Type: None): The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target NOT has been identified.
- G - No genomic profiling (Type: None): The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has not been sent for genomic profiling.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues